jardiance duo 5 mg850 mg
boehringer ingelheim israel ltd. - empagliflozin; metformin hydrochloride - film coated tablets - empagliflozin 5 mg; metformin hydrochloride 850 mg - metformin and empagliflozin - jardiance duo is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control• in patients inadequately controlled on their maximally tolerated dose of metformin alone.• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin.• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
glyxambi 10 mg5 mg
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.
glyxambi 25 mg5 mg
boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 25 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.
empagliflozin and metformin hydrochloride extended release tablets 25 mg/1000 mg 25mg + 1000mg oral solid ordinary other tablets
cipla ltd. - empagliflozin + metformin hydrochloride - oral solid ordinary other tablets - 25mg + 1000mg
empagliflozin and metformin hydrochloride extended release tablets 12.5 mg/1000 mg 12.5mg + 1000mg oral solid ordinary other tab
cipla limited - empagliflozin + metformin hydrochloride - oral solid ordinary other tablets - 12.5mg + 1000mg
empagliflozin and metformin hydrochloride extended release tablets 5 mg/1000 mg 5mg + 1000mg oral solid ordinary other tablets
cipla limited - empagliflozin + metformin hydrochloride - oral solid ordinary other tablets - 5mg + 1000mg
empagliflozin and metformin hydrochloride extended release tablets 10 mg/1000 mg 10mg + 1000mg oral solid ordinary other tablets
cipla ltd. - empagliflozin + metformin hydrochloride - oral solid ordinary other tablets - 10mg + 1000mg
emglyza-10 tablet
unisel pharma (k) limited apricot suites fourth parklands avenue, nairobi - empagliflozin - tablet - empagliflozin 10 mg - empagliflozin
emglyza-25 tablet
unisel pharma (k) ltd apricot suites fourth parklands avenue, nairobi - empagliflozin - tablet - empagliflozin 25 mg - empagliflozin
empa q 10mg tablet
q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - empagliflozin - tablet - empagliflozin 10mg - empagliflozin